Arzeda Overview
- Founded
- 2008
- Status
- Private
- Employees
- 38
- Latest Deal Type
- Later Stage VC
- Investors
- 13
Arzeda General Information
Description
Operator of a synthetic biology company intended to create novel proteins, enzymes, and specialty chemicals. The company develops a portfolio of enzymes and specialty chemicals for polymers, pharmaceuticals, industrial chemicals, and other advanced applications, enabling clients to access products that compete on performance, cost, and sustainability.
Contact Information
Website
www.arzeda.com
Ownership Status
Privately Held (backing)
Financing Status
Venture Capital-Backed
Primary Industry
Biotechnology
Other Industries
Specialty Chemicals
Primary Office
- 3421 Thorndyke Avenue West
- Seattle, WA 98119
- United States
+1 (206) 000-0000
Arzeda Timeline
Arzeda Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 9. Later Stage VC | 01-Nov-2021 | 000.00 | Completed | Generating Revenue | ||
| 8. Later Stage VC (Series B) | 22-Jul-2021 | 000.00 | 000.00 | 00000 | Completed | Generating Revenue |
| 7. Later Stage VC (Series B) | 24-Nov-2020 | 000 | 000.00 | 0000 | Completed | Generating Revenue |
| 6. Debt - PPP | 30-Apr-2020 | 00000 | 000.00 | Completed | Generating Revenue | |
| 5. Later Stage VC (Series A) | 30-Nov-2017 | 000.00 | 000.00 | 000.00 | Completed | Generating Revenue |
| 4. Grant | 28-Feb-2017 | 00.000 | 00000 | Completed | Generating Revenue | |
| 3. Seed Round | 23-Dec-2014 | 00000 | 00000 | 000 | Completed | Generating Revenue |
| 2. Grant | 30-Dec-2013 | $1.2M | Completed | Generating Revenue | ||
| 1. Grant | 08-Dec-2009 | $149K | Completed | Generating Revenue |
Arzeda Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series B | 0,000,000 | 00.000000 | 00.00 | 00.00 | 00 | 00.00 | 00.000 | |
| Series B-2 | 0,000,000 | 00.000000 | 00.00 | 00.00 | 00 | 00.00 | 0.000 | |
| Series B-1 | 000,000 | 00.000000 | 00.00 | 00.00 | 00 | 00.00 | 0.000 | |
| Series A | 3,186,929 | $0.000100 | $4.55 | $4.55 | 1x | $4.55 | 18.24% | |
| Seed | 364,630 | $0.000100 | $1 | $1 | 1x | $1 | 2.09% |
Arzeda Comparisons
Description
Primary
Industry
Industry
HQ Location
Employees
Total Raised
Post Valuation
Last Financing Details
Operator of a synthetic biology company intended to create novel proteins, enzymes, and specialty chemicals. The company
Biotechnology
Seattle, WA
38
As of 2021
000.00
0000000000 0
000.00
000 0000
iqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip ex ea commo
000000000 000000000
Boulder, CO
00
As of 0000
000.00
0000
0000-00-00
00000000000
000.00
00000000
e magna aliqua. Ut enim ad minim veniam, quis nostrud exercitation ullamco laboris nisi ut aliquip e
0000000000000
Saint Louis, MO
00000
As of 0000
000
0000-00-00
000000&0
Add Comparison
PitchBook’s comparison feature gives you a side-by-side look at key metrics for similar companies. Personalize which data points you want to see and create visualizations instantly.
Request a free trialArzeda Competitors (14)
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| DMC Biotechnologies | Venture Capital-Backed | Boulder, CO | 00 | 000.00 | 00000000000 | 000.00 |
| 00000000000000 | Corporate Backed or Acquired | Saint Louis, MO | 00000 | 000000&0 | ||
| 0000000 | Corporation | Roslin, United Kingdom | 0 | 0000000000 | ||
| 00000 00000 | Corporation | Basel, Switzerland | 00000 | 00000 | 00000000000 | 00000 |
| 00000 000 | Venture Capital-Backed | Cambridge, MA | 000 | 00000 | 000000000 | 00000 |
Arzeda Patents
Arzeda Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| AU-2019297508-A1 | Methods and compositions for preparing tagatose from fructose | Pending | 03-Jul-2018 | 00000000 | |
| CA-3105219-A1 | Methods and compositions for preparing tagatose from fructose | Pending | 03-Jul-2018 | 00000000 | |
| US-20200165639-A1 | Methods and compositions for preparing tagatose from fructose | Granted | 03-Jul-2018 | 00000000 | |
| US-11060119-B2 | Methods and compositions for preparing tagatose from fructose | Active | 03-Jul-2018 | 00000000 | 0 |
| EP-3818156-A1 | Methods and compositions for preparing tagatose from fructose | Pending | 03-Jul-2018 | C12P7/26 |
Arzeda Executive Team (7)
Arzeda Board Members (8)
| Name | Representing | Role | Since |
|---|---|---|---|
| Alexandre Zanghellini Ph.D | Arzeda | Co-Founder, Chief Executive Officer, Vice President, Research & Board Member | 000 0000 |
| Brian Loeb | Arzeda | Board Member | 000 0000 |
| Douglas Cameron Ph.D | Self | Board Member | 000 0000 |
| Jeffrey Klunzinger | OS Fund | Board Member | 000 0000 |
| Ronald Howell | WRF Capital | Board Member | 000 0000 |
Arzeda Signals
Growth Rate
0.80%
Weekly
Growth
Growth
Weekly Growth
0.80%, 93rd %ile
-35.5%.
530%
Size Multiple
219x
Median
Size Multiple
219x, 100th %ile
0.00x
0.95x.
413Kx
Key Data Points
Twitter Followers
5.5k
Similarweb Unique Visitors
15.0K
Majestic Referring Domains
314
PitchBook’s non-financial metrics help you gauge a company’s traction and growth using web presence and social reach.
Request a free trialArzeda Investors (13)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds | Contact Info |
|---|---|---|---|---|---|
| Circulate Capital | Impact Investing | Minority | 000 0000 | 000000 0 | |
| CGC Ventures | Venture Capital | Minority | 000 0000 | 000000 0 | |
| Sahsen Ventures | Venture Capital | Minority | 000 0000 | 000000 0 | |
| SynBio Innovation Accelerator | Accelerator/Incubator | Minority | 000 0000 | 000000 0 | |
| Bioeconomy Capital | Venture Capital | Minority | 000 0000 | 000000 0 |